CLINICAL_TRIALS
trial_result
· 2015-02-13
Clinical Trial Update: Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II [Phase 3]
Summary
Phase 3 trial evaluating high-dose BIBF 1120 (nintedanib) for idiopathic pulmonary fibrosis has completed. Results were posted in 2015.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2015-02-13